I-Mab (NASDAQ:NBP) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of I-Mab (NASDAQ:NBP) from a sell rating to a strong sell rating in a research report sent to investors on Monday morning,Wall Street Zen reports.

A number of other research firms also recently commented on NBP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of I-Mab in a research report on Thursday, August 27th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of I-Mab in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.00.

I-Mab Stock Down 4.5%

NBP stock opened at $1.70 on Monday. The business has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.14. The stock has a market cap of $196.60 million, a price-to-earnings ratio of -4.72 and a beta of 1.50. I-Mab has a fifty-two week low of $1.46 and a fifty-two week high of $6.79.

I-Mab (NASDAQ:NBP) last announced its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) EPS for the quarter. As a group, sell-side analysts anticipate that I-Mab will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.